Keytruda (Pembrolizumab) Denied by Insurance

Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor developed by Merck that has transformed cancer treatment across more than 40 tumor types. It is FDA-approved for melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, colorectal cancer, endometrial carcinoma, tumor mutational burden-high cancers, and several other malignancies. Despite its broad approval and life-extending outcomes, Keytruda is frequently denied by insurance — often for technical reasons that can be challenged and overturned.

Why Insurance Companies Deny Keytruda

PD-L1 testing requirements are among the most common denial triggers. Some insurers require documented PD-L1 expression levels above a certain threshold before approving Keytruda for certain indications, particularly non-small cell lung cancer. If PD-L1 testing was not performed, or if results fall below the insurer's threshold, coverage may be denied even when the oncologist believes Keytruda is the most appropriate treatment.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization is required for every Keytruda prescription. The PA process for a cancer immunotherapy is extensive and typically includes diagnostic pathology reports, biomarker test results (PD-L1, MSI/dMMR, TMB-H where applicable), staging information, prior treatment history, and oncologist notes. Missing any of these elements can result in an automatic denial.

Line-of-therapy restrictions limit when insurers will cover Keytruda. Some policies only approve it as second-line treatment after failure of standard chemotherapy, even when the FDA label and clinical guidelines support first-line use for specific tumor types. Insurers sometimes lag behind evolving treatment standards.

Off-label use denials occur when Keytruda is prescribed for a tumor type or patient population that is FDA-approved but not yet reflected in the insurer's internal coverage policy. This is particularly common in oncology, where approvals sometimes outpace insurer policy updates.

Clinical trial enrollment requirements appear in some Medicare and managed care policies, particularly for newer or expanded Keytruda indications. CMS and some commercial insurers have required enrollment in a registry or clinical trial as a condition of coverage.

How to Appeal a Keytruda Denial

Submit complete biomarker documentation. If your denial cites missing or insufficient PD-L1 or other biomarker testing, work with your oncologist's office to provide all pathology reports, next-generation sequencing results, and biomarker assay data. Clarify that testing was performed with an FDA-approved companion diagnostic assay.

Document the treatment line. If your insurer denied Keytruda as first-line therapy, have your oncologist provide a detailed letter explaining why first-line immunotherapy is appropriate per NCCN guidelines for your specific tumor type and PD-L1 expression level. NCCN (National Comprehensive Cancer Network) guidelines carry significant weight in insurance appeals because many insurers contractually agree to cover NCCN Category 1 or 2A recommendations.

Cite FDA label and NCCN guidelines. Include the relevant section of the Keytruda FDA prescribing information and the applicable NCCN guideline recommendation in your appeal. For example, if Keytruda is a Category 1 preferred treatment for your tumor type and PD-L1 score, state this explicitly.

Request an expedited appeal. Cancer treatment delays can be life-threatening. You are entitled to an expedited internal appeal — typically a 72-hour decision — when a delay in care would seriously jeopardize your health. Your oncologist should support the request with a statement documenting the urgency.

Push for peer-to-peer review. An oncologist who specializes in your cancer type speaking directly with the insurer's medical reviewer is one of the most powerful tools in a Keytruda appeal. Reviewers who are not oncology specialists may not appreciate the clinical nuances that justify first-line immunotherapy, and a peer-to-peer conversation can resolve this quickly.

Escalate to External Independent Review: Complete Guide" class="auto-link">external review. If your internal appeal is denied, an independent external reviewer — often an oncologist — will evaluate the denial without the financial bias of your insurer. Keytruda denials for FDA-approved indications are frequently overturned in external review.

Medicare Coverage Considerations

For Medicare patients, Keytruda administered in an outpatient hospital or physician's office setting is covered under Part B. Keytruda obtained through specialty pharmacy for home administration falls under Part D. Coverage gaps and high cost-sharing can still create access problems even with Medicare, making supplemental coverage or patient assistance programs important.

Patient Assistance Programs

Merck offers the Merck Access Program for patients who cannot afford Keytruda. The program includes copay assistance for commercially insured patients, as well as a free drug program for uninsured or underinsured patients who meet income eligibility criteria. Contact Merck Access at 1-855-257-3932 or visit merck.com/patient-assistance-program.

Keytruda costs approximately $15,000–$20,000 per month at list price. Do not wait for your appeal to resolve before contacting the Merck Access Program — free drug may be available on an urgent basis for cancer patients facing imminent treatment gaps.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?